KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Petmed Express (PETS) Common Equity (2016 - 2025)

Historic Common Equity for Petmed Express (PETS) over the last 17 years, with Q4 2025 value amounting to $32.8 million.

  • Petmed Express' Common Equity fell 6593.4% to $32.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $32.8 million, marking a year-over-year decrease of 6593.4%. This contributed to the annual value of $85.1 million for FY2025, which is 1198.89% down from last year.
  • Petmed Express' Common Equity amounted to $32.8 million in Q4 2025, which was down 6593.4% from $43.1 million recorded in Q3 2025.
  • Over the past 5 years, Petmed Express' Common Equity peaked at $141.5 million during Q3 2021, and registered a low of $32.8 million during Q4 2025.
  • For the 5-year period, Petmed Express' Common Equity averaged around $104.5 million, with its median value being $102.3 million (2023).
  • In the last 5 years, Petmed Express' Common Equity soared by 866.93% in 2021 and then crashed by 6593.4% in 2025.
  • Quarter analysis of 5 years shows Petmed Express' Common Equity stood at $140.9 million in 2021, then decreased by 18.48% to $114.9 million in 2022, then fell by 12.89% to $100.1 million in 2023, then fell by 3.87% to $96.2 million in 2024, then plummeted by 65.93% to $32.8 million in 2025.
  • Its Common Equity stands at $32.8 million for Q4 2025, versus $43.1 million for Q3 2025 and $51.5 million for Q2 2025.